Spondyloarthritis & psoriatic arthritis

Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe

Rheumatology (Oxford)Published Cross-sectional study

Authors' conclusion

Differences in symptomatic burden and care were observed between regions.

Study context

Population
Consecutive patients with axial SpA (axSpA) reported by rheumatologists in the USA and 5EU, March–November 2021349 rheumatologists
Participants
2,750 patients
Exposure
USA vs five European countries
  • USAn = 656
  • 5EUn = 2,094reference
Methodological detailsreal-world survey, Adelphi axSpA Disease Specific Programme, multinational (USA and 5EU), 1011 (36.8%) patients self-reported data, Alignment quantified using weighted kappa
  • Real-world survey
  • Adelphi axSpA Disease Specific Programme
  • Multinational (USA and 5EU)
  • 1011 (36.8%) patients self-reported data
  • Alignment quantified using weighted kappa

Main finding

As reported in the abstract

  • Symptomatic burden and care differed between regions

Observational data: associations, not effects.

Further findings

OutcomeUSA5EUP value
Number of symptoms at diagnosisMean6.0 (SD 4.4)6.4 (SD 4.3)P = 0.0657
Number of symptoms at data collectionMean3.3 (SD 3.3)2.3 (SD 2.8)P < 0.0001
Physician-patient alignment (weighted kappa)
κ, severity at diagnosis0.370.47
κ, severity at treatment initiation0.320.42
κ, severity at data collection0.320.61
κ, treatment satisfaction0.350.42
Consultations in previous 12 monthsMean5.2 (SD 3.4)6.5 (SD 5.1)P = 0.0008

Physician-patient alignment (weighted kappa)

Alignment lower in the USA than in 5EU

Consultations in previous 12 months

Mean hospitalizations similar

Original publication

Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe. Rheumatology (Oxford). Published 20 March 2026. doi:10.1093/rheumatology/keag106

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.